Non-adenomatous non-epithelial carcinoma (hemangiopericytoma) of prostate treated with conservative surgery followed by adjuvant chemoradiation

B. Chakrabarti MD, *S.K. Ghosh MD, *B. Basu MBBS, *P. Gupta MD, *S. Ghorai MD, *S.G. Ray MD, *and C. Das MBBS*

ABSTRACT

Hemangiopericytoma is a malignant vascular tumour of soft tissue. Microscopically, the tumour shows tightly packed cellular areas surrounding thin-walled branching blood vessels. Traditionally, these tumours are treated using wide surgical excision. Only a very few cases of hemangiopericytoma of the prostate have been described worldwide. The feasibility of managing such a case with a combination of conservative surgery and adjuvant anti-malignancy treatment is unexplored. Here, we report a case of hemangiopericytoma of the prostate treated with local excision, with preservation of prostate, followed by adjuvant radiotherapy and chemotherapy.

2. CASE DESCRIPTION

A 56-year-old man attended our oncology unit with a history of excision of a prostatic nodule about 6 weeks earlier. The patient initially attended a local doctor, reporting a history of increased frequency of micturition for 2 months and increased temperature for 1 month. Routine examination was normal, and urine culture was negative. The fever and pain subsided after treatment with antibiotics, but the increased frequency of micturition persisted. Digital rectal examination revealed a mildly enlarged nodular prostate, and pelvic sonography was done. A thick-walled nodule (38 x 36 x 35 mm) was detected in the prostate. Levels of serum prostate-specific antigen (PSA) was 1 ng/mL. Cystoscopy showed no intravesicular lesions. Transrectal core needle biopsy diagnosed a probable case of alveolar rhabdomyosarcoma. The patient refused radical surgery, and only local excision of the prostatic nodule was done.

We conclude that conservative surgery followed by adjuvant radiation and chemotherapy, with subsequent close follow-up, may adequately control localized disease in selected cases of hemangiopericytoma of the prostate. The role of conservative surgery in tumours located at other sites has yet to be defined.

KEY WORDS

Carcinoma, prostate, hemangiopericytoma, treatment
HMB45, synaptophysin, and chromogranin. Hence, a diagnosis of hemangiopericytoma was made.

Postoperative magnetic resonance imaging showed no residual prostate nodule. Prostate was normal in size, but irregular in shape, and enlarged pelvic lymph nodes were reported on imaging. Image-guided biopsy of the nodes demonstrated spindle cells around branching vascular channels. Routine metastatic work-up, serum PSA, and serum carcinoembryonic antigen (CEA) levels were normal.

The patient refused any form of further surgery. Simple local excision of the prostate nodule without any adjuvant treatment would not have sufficed, because positive pelvic nodes had been left behind. The patient was therefore given good supportive care and was treated postoperatively with external-beam radiotherapy followed by 6 cycles of adjuvant combination chemotherapy. External-beam radiotherapy was delivered using three-dimensional computerized treatment planning in a 3-field technique (1 anterior and 2 posterior oblique) delivering a dose of 40 Gy in 20 fractions to pelvis, followed by 24 Gy in 12 fractions as a boost to prostate, with adequate margin. Adjuvant combination chemotherapy delivered at intervals of 3 weeks consisted of doxorubicin 60 mg/m$^2$ on day 1 and ifosfamide 2 g/m$^2$ daily for 4 days, together with MESNA and filgrastim support.

A CT scan 4 weeks after completion of treatment showed regression of the lymph nodes and a normal-appearing prostate. Serum PSA and CEA were normal throughout the period of treatment. Patient has been followed in our department for 42 months to the date of writing. He is asymptomatic, and follow-up has been uneventful, except for occasional bouts of diarrhea.

3. DISCUSSION

Hemangiopericytoma is an unusual perivascular tumour first described by Stout and Murray in 1942. It features uncontrolled proliferation of pericytes, which are cells described by Zimmermann in 1923. The tumour represents 2%–3% of all soft-tissue sarcomas in humans. It usually occurs in elderly patients during the 4th and 5th decades. The common sites are deep soft tissue, lower extremities, pelvis, and retroperitoneum. Head-and-neck lesions are also reported, and rare cases of primary hemangiopericytoma of bone may be found in pelvis, proximal femur, vertebrae, or humerus.

This tumour is generally rare in the urogenital system including the kidney; the other sites include the bladder, the prostate, and the spermatic cord. Hemangiopericytoma usually presents as a painless mass. Initial symptoms of the rare genitourinary tumours included hematuria, frequency of urination, and lower urinary tract obstruction.

Macroscopically, the tumour is soft and rubbery; microscopically, it is characterized by tightly packed small spindle cells surrounding thin-walled branching blood vessels ("stag horn" pattern). Microscopically, benign and malignant forms are distinguishable. Malignant forms are characterized by increased cellularity, prominent mitotic activity, and foci of necrosis or hemorrhage. Features indicating poor prognosis include increased cellularity, necrosis, hemorrhage, and mitotic figures exceeding 4/10 HPF. Tumours exhibiting nuclear atypia with more than 4/10 HPF may either recur or metastasize. Metastases are usually to lung and bone; lymph node metastasis is uncommon.

The spread pattern is principally hematogenous. Invasion of the bladder wall in urogenital tumours has been reported. Recurrence precedes metastasis in more than two thirds of patients with evidence of metastasis. The 10-year survival rate is 70%. The overall 5-year survival rate for microscopically dysplastic hemangiopericytoma is somewhat less than 50%.

The differential diagnosis of this lesion in prostate includes malignant fibrous histiocytoma, sarcomas, malignant peripheral nerve sheath tumour, and sarcomatoid carcinoma. Differentiation uses immunohistochemistry. Tissue immunohistochemistry shows immunoreactivity for vimentin (variable intensity), factor VIII-related antigen, HLA-DR antigen, and CD34. No staining or reaction with factor VIII-related antigen, Ulex europaeus lectin, α-smooth muscle actin, desmin, myoglobin, low- or high-molecular-weight cytokeratin, or epithelial membrane antigen occurs.

Traditionally, these tumours are treated using surgical excision. Many authors have suggested that resectability may be the single most important determinant of clinical outcome. The role of adjuvant treatment is poorly defined. Use of adjuvant radiation therapy reduces the risk of local and distant recurrence.

Only a very few cases of hemangiopericytoma of the prostate have been described worldwide. Some patients were treated with transurethral resection of the prostate, but they later died of late recurrence in up to 50% of cases and disseminated disease of the lung. The other patients were recommended to have early aggressive therapy and long-term follow-up. It was concluded that genitourinary tumours should be considered malignant and treated aggressively. The feasibility of managing such a case with a combination of conservative surgery and adjuvant anti-malignancy treatment had largely been unexplored.

4. CONCLUSIONS

Conservative surgery followed by adjuvant radiation and chemotherapy, and subsequent close follow-up may adequately control localized disease in selected cases of hemangiopericytoma of the prostate. The role of conservative surgery in such tumours at other sites has yet to be defined.
5. REFERENCES

1. Stout AP, Murray MR. Hemangiopericytoma: a vascular tumor featuring Zimmermann’s pericytes. Am Surg 1942;116:26–33.
2. Velasco A, Mora X, Baeza R, Guzmán S. Hemangiopericytoma: report of 4 cases [Spanish]. Rev Med Chil 1993;121:1305–8.
3. Argyropoulos A, Liakatas I, Lykourinas M. Renal haemangiopericytoma: the characteristics of a rare tumour. BJU Int 2005;95:943–7.
4. Enzinger FM, Smith BH. Hemangiopericytoma. An analysis of 106 cases. Hum Pathol 1976;7:61–82.
5. Walike JW, Bailey BJ. Head and neck hemangiopericytoma. Arch Otolaryngol 1971;93:345–53.
6. Seibert JJ, Seibert RW, Weisenburger DS, Allsbrook W. Multiple congenital hemangiopericytomases of the head and neck. Laryngoscope 1978;88:1006–12.
7. DelGaudio JM, Garetz SL, Bradford CR, Stenson KM. Hemangiopericytoma of the oral cavity. Otolaryngol Head Neck Surg 1996;114:339–40.
8. Kothari PS, Murphy M, Howells GL, Williams DM. Hemangiopericytoma: a report of two cases arising on the lip. Br J Oral Maxillofac Surg 1996;34:454–56.
9. Lin JC, Hsu CY, Jan JS, Chen JT. Malignant hemangiopericytoma of the floor of the mouth: report of a case and review of the literature. J Oral Maxillofac Surg 1996;54:1020–3.
10. Chen KT. Hemangiopericytoma of the prostate. J Surg Oncol 1987;35:42–3.
11. Baumgartner G, Gaeta J, Wajszman Z, Merrin C. Hemangiopericytoma of the urinary bladder: a case report and review of the literature. J Surg Oncol 1976;8:281–6.
12. Siemens DR, Nickel JC, Young ID. Haemangiopericytoma of the spermatic cord. Br J Urol 1998;81:329–30.
13. Perkins P, Weiss SW. Spindle cell hemangioendothelioma. An analysis of 78 cases with reassessment of its pathogenesis and biologic behavior. Am J Surg Pathol 1996;20:1196–204.
14. Bocchi L, Lazzeroni L, Maggi M. The surgical treatment of metastases in long bones. Ital J Orthop Traumatol 1988;14:167–73.
15. Ishiguro K, Yamakoshi T, Okishio N, Tamai H, Naide Y, Kasa Hara M. Hemangiopericytoma of the prostate: a case report [Japanese]. Hinyokika Kiyo 1984;30:934–1.
16. Sukumar S, Bhat HS, Nair B, Saheed CSM, Sanjeev KV. Haemangiopericytoma of the prostate. A rare case report and novel treatment strategy. Afr J Urol 2005;11:236–7.
17. Takano K, Suzuki N, Saito H, et al. A case of hemangiopericytoma in the pelvic retroperitoneum and review of literature of hemangiopericytoma in the retroperitoneal space in Japan [Japanese]. Nippon Geka Gakkai Zasshi 1985;86:959–65.

Correspondence to: Bikramjit Chakrabarti, Nivedita Apartment, 1/96, M.M. Ghosh Road, Kolkata 700 074 West Bengal, India.
E-mail: jtbkm@yahoo.com

* Department of Radiotherapy, Calcutta Medical College, Kolkata, India.